The BCL-2 Inhibitor APG-2575 Resets Tumor-Associated Macrophages toward the M1 Phenotype, Promoting a Favorable Response to Anti-PD-1 Therapy via NLRP3 Activation

Using single-cell RNA sequencing, researchers found that APG-2575 polarized M2-like immunosuppressive macrophages toward the M1-like immunostimulatory phenotype with increased CCL5 and CXCL10 secretion, restoring T-cell function and promoting a favorable immunotherapy response.